Breast Cancer

**Endocrine Therapy**

- **ER/PR-POSITIVE HER2 NEGATIVE**
  - **HER2 POSITIVE**
  - **"TRIPLE NEGATIVE" EP/PR–NEGATIVE HER2-NEGATIVE**

<table>
<thead>
<tr>
<th>Pre-Op Therapy</th>
<th>Surgical Therapy</th>
<th>Adjuvant Therapy</th>
<th>1st line MBC Therapy</th>
<th>2nd line MBC Therapy</th>
<th>3rd line MBC Therapy</th>
<th>“Heavily Pre-treated” Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**CDK 4/6i + PARPi**

IRB# 6256-ISPY2 Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2

No Trial Currently Available

IRB# 17461 S1418
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy

No Trials Currently Available

IRB#19200 DS-8201a Compared to Treatment of Physician’s Choice for HER2-low Unresectable/Metastatic Breast Cancer

IRB#19358 Elacestran Monotherapy vs. SOC for Advanced BC following CDK4/6 Inhibitor Therapy

IRB# 17887 SGN-LIV1A Part E

IRB#19830 T-DM1 and Palbociclib in Metastatic HER2+ BC

IRB#20112 T-DM1 and Tucatinib/Placebo in Metastatic HER2+ BC

IRB 15588 SMMART

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

08/13/2018